Nortiva Bio, Inc. has officially launched as a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies using its LYNX™ drug delivery platform. The platform aims to convert daily medications into once-monthly doses, with applications including a monthly oral contraceptive supported by a $5 million grant from the Gates Foundation. Nortiva plans to expand its pipeline through partnerships with biotech and pharmaceutical companies to create long-acting oral versions of existing therapies. The LYNX platform promises improved medication adherence and optimized patient outcomes.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/nortiva-bio-launches-to-develop-long-acting-oral-medicines
